Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients

Nephrology Dialysis Transplantation

Volumn 28, Issue 5, 2013, Pages 1232-1240

  Zitt, Emanuel ^a,b   König, Matthias ^a   Vychytil, Andreas ^c   Auinger, Martin ^d   Wallner, Manfred ^e   Lingenhel, Gernot ^f   Schilcher, Gernot ^g   Rudnicki, Michael ^h   Salmhofer, Hermann ⁱ   Lhotta, Karl ^a,b  

^a ACADEMIC TEACHING HOSPITAL FELDKIRCH   (Austria)

^b Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d HIETZING HOSPITAL   (Austria)

^e Klinikum Wels Grieskirchen GmbH   (Austria)

^f Dialysis   (Austria)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁱ PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

calcific uraemic arteriolopathy; calciphylaxis; dialysis; end stage renal disease; sodium thiosulphate

Indexed keywords

ANTIBIOTIC AGENT; CINACALCET; SODIUM THIOSULFATE;

ADULT; AGED; AMPUTATION; ARTICLE; AUSTRIA; CALCINOSIS; CLINICAL ARTICLE; COHORT ANALYSIS; DEMOGRAPHY; DRUG RESPONSE; DRUG USE; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY;

CALCIFIC URAEMIC ARTERIOLOPATHY; CALCIPHYLAXIS; DIALYSIS; END-STAGE RENAL DISEASE; SODIUM THIOSULPHATE;

AGED; CALCIPHYLAXIS; CHELATING AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERVENTION STUDIES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THIOSULFATES;

EID: 84877955595     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs548     Document Type: Article

References (39)

1. Brandenburg VM, Cozzolino M, Ketteler M. Calciphylaxis: a still unmet challenge. J Nephrol 2011; 24: 142-148
2. Rogers NM, Coates PT. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens 2008; 17: 629-634
3. Weenig RH, Sewell LD, Davis MD et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007; 56: 569-579
4. Farah M, Crawford RI, Levin A et al. Calciphylaxis in the current era: emerging 'ironic' features? Nephrol Dial Transplant 2011; 26: 191-195
5. Nigwekar SU, Wolf M, Sterns RH et al. Calciphylaxis from non-uremic causes: a systematic review. Clin J Am Soc Nephrol 2008; 3: 1139-1143
6. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002; 61: 2210-2217
7. Courtney MJ, Pannu N. Calcific uremic arteriolopathy should be treated conservatively. Semin Dial 2010; 23: 34-37
8. Vedvyas C, Winterfield LS, Vleugels RA. Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermato 2012; 67: e253-e60
9. Velasco N, MacGregor MS, Innes A et al. Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy? Nephrol Dial Transplant 2006; 21: 1999-2004
10. Cicone JS, Petronis JB, Embert CD et al. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004; 43: 1104-1108
11. Hayden MR, Goldsmith DJ. Sodium thiosulfate: new hope for the treatment of calciphylaxis. Semin Dial 2010; 23: 258-262
12. New N, Mohandas J, John GT et al. Calcific uremic arteriolopathy in peritoneal dialysis populations. Int J Nephrol 2011: 982854
13. Noureddine L, Landis M, Patel N et al. Efficacy of sodium thiosulfate for the treatment for calciphylaxis. Clin Nephrol 2011; 75: 485-490
14. Ackermann F, Levy A, Daugas E et al. Sodium thiosulfate as first-line treatment for calciphylaxis. Arch Dermatol 2007; 143: 1336-1337; author reply 1338
15. Araya CE, Fennell RS, Neiberger RE et al. Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol 2006; 1: 1161-1166
16. Baker BL, Fitzgibbons CA, Buescher LS. Calciphylaxis responding to sodium thiosulfate therapy. Arch Dermatol 2007; 143: 269-270
17. Bazari H, Jaff MR, Mannstadt M et al. Case records of the Massachusetts General Hospital. Case 7-2007. A 59-year-old woman with diabetic renal disease and nonhealing skin ulcers. N Engl J Med 2007; 356: 1049-1057
18. Brucculeri M, Cheigh J, Bauer G et al. Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semin Dial 2005; 18: 431-434
19. Guerra G, Shah RC, Ross EA. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: case report. Nephrol Dial Transplant 2005; 20: 1260-1262
20. Hayden MR, Kolb LG, Khanna R. Calciphylaxis and the cardio-metabolic syndrome. J Cardiometab Syndr 2006; 1: 76-79
21. Kyritsis I, Gombou A, Griveas I et al. Combination of sodium thiosulphate, cinacalcet, and paricalcitol in the treatment of calci-phylaxis with hyperparathyroidism. Int J Artif Organs 2008; 31: 742-744
22. Mataic D, Bastani B. Intraperitoneal sodium thiosulfate for the treatment of calciphylaxis. Ren Fail 2006; 28: 361-363
23. Meissner M, Bauer R, Beier C et al. Sodium thiosulphate as a promising therapeutic option to treat calciphylaxis. Dermatology 2006; 212: 373-376
24. Sood AR, Wazny LD, Raymond CB et al. Sodium thiosulfate-based treatment in calcific uremic arteriolopathy: a consecutive case series. Clin Nephrol 2011; 75: 8-15
25. Subramaniam K, Wallace H, Sinniah R et al. Complete resolution of recurrent calciphylaxis with long-term intravenous sodium thiosulfate. Australas J Dermatol 2008; 49: 30-34
26. Tindni A, Gaurav K, Panda M. Non-healing painful ulcers in a patient with chronic kidney disease and role of sodium thiosul-fate: a case report. Cases J 2008; 1: 178
27. Mazhar AR, Johnson RJ, Gillen D et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001; 60: 324-332
28. Rogers NM, Coates PT. Calcific uremic arteriolopathy-the argument for hyperbaric oxygen and sodium thiosulfate. Semin Dial 2010; 23: 38-42
29. Schlieper G, Brandenburg V, Ketteler M et al. Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol 2009; 5: 539-543
30. Yatzidis H. Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Clin Nephrol 1985; 23: 63-67
31. Hayden MR, Goldsmith D, Sowers JR et al. Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosul-fate. Int Urol Nephrol 2008; 40: 443-451
32. Adirekkiat S, Sumethkul V, Ingsathit A et al. Sodium thiosul-fate delays the progression of coronary artery calcification in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 1923-1929
33. O'Neill WC. Treatment of vascular calcification. Kidney Int 2008; 74: 1376-1378
34. Pasch A, Schaffner T, Huynh-Do U et al. Sodium thiosulfate prevents vascular calcifications in uremic rats. Kidney Int 2008; 74: 1444-1453
35. Mawad HW, Sawaya BP, Sarin R et al. Calcific uremic arteriolo-pathy in association with low turnover uremic bone disease. Clin Nephrol 1999; 52: 160-166
36. Kurz P, Monier-Faugere MC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861
37. Singh RP, Derendorf H, Ross EA. Simulation-based sodium thio-sulfate dosing strategies for the treatment of calciphylaxis. Clin J Am Soc Nephrol 2011; 6: 1155-1159
38. Farese S, Stauffer E, Kalicki R et al. Sodium thiosulfate pharmaco-kinetics in hemodialysis patients and healthy volunteers. Clin J Am Soc Nephrol 2011; 6: 1447-1455
39. Baldwin C, Farah M, Leung M et al. Multi-intervention management of calciphylaxis: a report of 7 cases. Am J Kidney Dis 2011; 58: 988-991